Writers and Erasers of Histone Lysine methylation with Clinically Applied Modulators: Promising Target for Cancer Therapy

Author(s): Yi-Chao Zheng, Jin-Lian Ma, Ying Liu, Hong M. Liu

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 39 , 2016

Become EABM
Become Reviewer
Call for Editor


Histone lysine methylation can be modified by various writers and erasers. Different from other epigenetic modifications, mono-, di, and tri- methylation distinctly modulate chromatin structure and thereby contribute to the regulation of DNA-based nuclear processes such as transcription, replication and repair on their target genes depending on different sites. Modulators with opposing catalytic activities dynamically and precisely control levels of histone lysine methylation, and individual enzymes within these families have become candidate oncology targets in recent years. Until now, plenty of medicinal chemists try to pursue potent and selective inhibitor for KMTs and KDMs in order to have the potential anti-cancer agent, and several of the inhibitors have already enrolled in clinic. Here, we discuss three histone lysine methylation modulators with their inhibitors in clinical trials.

Keywords: Lysine methyltransferase, lysine demethylase, inhibitor, cancer.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [5943 - 5947]
Pages: 5
DOI: 10.2174/1381612822666160715125417
Price: $65

Article Metrics

PDF: 34